Durk F. Zandstra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Durk F. Zandstra has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
H K Van Saene
5 shared publicationsC P Stoutenbeek
4 shared publicationsD R Miranda
3 shared publications- Heleen M. Oudemans-Van Straaten
Department of Intensive Care Medicine, Onze Lieve Vrouwe Gasthuis, Oosterpark 9, 1091 AC Amsterdam, The Netherlands
2 shared publications Hendrick Kf van Saene
School of Clinical Sciences, University of Liverpool, Liverpool L69 3GA, UK
2 shared publications- Hkf van Saene
Department of Medical Microbiology, University of Liverpool, UK
2 shared publications
Latest Publications
- Open Access
- 17 October 2011
- Published by Springer Nature in Critical Care
- Vol. 15 (5) , R240
Presence of tobramycin in blood and urine during selective decontamination of the digestive tract in critically ill patients, a prospective cohort study
Introduction: Tobramycin is one of the components used for selective decontamination of the digestive tract (SDD), applied to prevent colonization and subsequent infections in critically ill patients. Tobramycin is administered in the oropharynx and gastrointestinal tract and is normally not absorbed. However, critical illness may convey gut barrier failure. The aim of the study was to assess the prevalence and amount of tobramycin leakage from the gut into the blood, to quantify tobramycin excretion in urine, and to determine the association of tobramycin leakage with markers of circulation, kidney function and other organ failure. Methods: This was a prospective observational cohort study. The setting was the 20-bed closed format-mixed ICU of a teaching hospital. The study population was critically ill patients with an expected stay of more than two days, receiving SDD with tobramycin, polymyxin-E and amphotericin-B four times daily in the oropharynx and stomach. Tobramycin concentration was measured in serum (sensitive high performance liquid chromatography - mass spectrometry/mass spectrometry (HLPC-MS/MS) assay) and 24-hour urine (conventional immunoassay), in 34 patients, 24 hours after ICU admission, and in 71 patients, once daily for 7 days. Tobramycin leakage was defined as tobramycin detected in serum at least once (> 0.05 mg/L). Ototoxicity was not monitored. Results: Of the 100 patients with available blood samples, 83 had tobramycin leakage. Median highest serum concentration for each patient was 0.12 mg/L; 99% of the patients had at least one positive urinary sample (> 0.5 mg/L), 49% had a urinary concentration ≥ 1 mg/L. The highest tobramycin serum concentration was significantly associated with vasopressor support, renal and hepatic dysfunction, and C-reactive protein. At binary logistic regression analysis, high dopamine dose and low urinary output on Day 1 were the significant predictors of tobramycin leakage. Nephrotoxicity could not be shown. Conclusions: The majority of acute critically ill patients treated with enteral tobramycin as a component of SDD had traces of tobramycin in the blood, especially those with severe shock, inflammation and subsequent acute kidney injury, suggesting loss of gut barrier and decreased renal removal. Unexpectedly, urinary tobramycin was above the therapeutic trough level in half of the patients. Nephrotoxicity could not be demonstrated.
- 17 October 2011
- Published by Springer Nature in Critical Care
- Vol. 15 (5) , R240
Open AccessPresence of tobramycin in blood and urine during selective decontamination of the digestive tract in critically ill patients, a prospective cohort study
Introduction: Tobramycin is one of the components used for selective decontamination of the digestive tract (SDD), applied to prevent colonization and subsequent infections in critically ill patients. Tobramycin is administered in the oropharynx and gastrointestinal tract and is normally not absorbed. However, critical illness may convey gut barrier failure. The aim of the study was to assess the prevalence and amount of tobramycin leakage from the gut into the blood, to quantify tobramycin excretion in urine, and to determine the association of tobramycin leakage with markers of circulation, kidney function and other organ failure. Methods: This was a prospective observational cohort study. The setting was the 20-bed closed format-mixed ICU of a teaching hospital. The study population was critically ill patients with an expected stay of more than two days, receiving SDD with tobramycin, polymyxin-E and amphotericin-B four times daily in the oropharynx and stomach. Tobramycin concentration was measured in serum (sensitive high performance liquid chromatography - mass spectrometry/mass spectrometry (HLPC-MS/MS) assay) and 24-hour urine (conventional immunoassay), in 34 patients, 24 hours after ICU admission, and in 71 patients, once daily for 7 days. Tobramycin leakage was defined as tobramycin detected in serum at least once (> 0.05 mg/L). Ototoxicity was not monitored. Results: Of the 100 patients with available blood samples, 83 had tobramycin leakage. Median highest serum concentration for each patient was 0.12 mg/L; 99% of the patients had at least one positive urinary sample (> 0.5 mg/L), 49% had a urinary concentration ≥ 1 mg/L. The highest tobramycin serum concentration was significantly associated with vasopressor support, renal and hepatic dysfunction, and C-reactive protein. At binary logistic regression analysis, high dopamine dose and low urinary output on Day 1 were the significant predictors of tobramycin leakage. Nephrotoxicity could not be shown. Conclusions: The majority of acute critically ill patients treated with enteral tobramycin as a component of SDD had traces of tobramycin in the blood, especially those with severe shock, inflammation and subsequent acute kidney injury, suggesting loss of gut barrier and decreased renal removal. Unexpectedly, urinary tobramycin was above the therapeutic trough level in half of the patients. Nephrotoxicity could not be demonstrated.
- Open Access
- 1 January 2011
- Published by Springer Nature in Critical Care
- Vol. 15 (2) , 411
Selective digestive decontamination is superior to selective oropharyngeal decontamination
- 1 January 2011
- Published by Springer Nature in Critical Care
- Vol. 15 (2) , 411
Open AccessSelective digestive decontamination is superior to selective oropharyngeal decontamination
- Open Access
- 10 December 2010
- Published by Springer Nature in Critical Care
- Vol. 14 (6) , R224
Mean glucose during ICU admission is related to mortality by a U-shaped curve in surgical and medical patients: a retrospective cohort study
Introduction: Lowering of hyperglycemia in the intensive care unit (ICU) is widely practiced. We investigated in which way glucose regulation, defined as mean glucose concentration during admission, is associated with ICU mortality in a medical and a surgical cohort. Methods: Retrospective database cohort study including patients admitted between January 2004 and December 2007 in a 20-bed medical/surgical ICU in a teaching hospital. Hyperglycemia was treated using a computerized algorithm targeting for glucose levels of 4.0-7.0 mmol/l. Five thousand eight hundred twenty-eight patients were eligible for analyses, of whom 1,339 patients had a medical and 4,489 had a surgical admission diagnosis. Results: The cohorts were subdivided in quintiles of increasing mean glucose. We examined the relation between these mean glucose strata and mortality. In both cohorts we observed the highest mortality in the lowest and highest strata. Logistic regression analysis adjusted for age, sex, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, admission duration and occurrence of severe hypoglycemia showed that in the medical cohort mean glucose levels 8.4 mmol/l and in the surgical cohort mean glucose levels < 7.0 mmol/l and >9.4 mmol/l were associated with significantly increased ICU mortality (OR 2.4-3.0 and 4.9-6.2, respectively). Limitations of the study were its retrospective design and possible incomplete correction for severity of disease. Conclusions: Mean overall glucose during ICU admission is related to mortality by a U-shaped curve in medical and surgical patients. In this cohort of patients a 'safe range' of mean glucose regulation might be defined approximately between 7.0 and 9.0 mmol/l.
- 10 December 2010
- Published by Springer Nature in Critical Care
- Vol. 14 (6) , R224
Open AccessMean glucose during ICU admission is related to mortality by a U-shaped curve in surgical and medical patients: a retrospective cohort study
Introduction: Lowering of hyperglycemia in the intensive care unit (ICU) is widely practiced. We investigated in which way glucose regulation, defined as mean glucose concentration during admission, is associated with ICU mortality in a medical and a surgical cohort. Methods: Retrospective database cohort study including patients admitted between January 2004 and December 2007 in a 20-bed medical/surgical ICU in a teaching hospital. Hyperglycemia was treated using a computerized algorithm targeting for glucose levels of 4.0-7.0 mmol/l. Five thousand eight hundred twenty-eight patients were eligible for analyses, of whom 1,339 patients had a medical and 4,489 had a surgical admission diagnosis. Results: The cohorts were subdivided in quintiles of increasing mean glucose. We examined the relation between these mean glucose strata and mortality. In both cohorts we observed the highest mortality in the lowest and highest strata. Logistic regression analysis adjusted for age, sex, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, admission duration and occurrence of severe hypoglycemia showed that in the medical cohort mean glucose levels 8.4 mmol/l and in the surgical cohort mean glucose levels < 7.0 mmol/l and >9.4 mmol/l were associated with significantly increased ICU mortality (OR 2.4-3.0 and 4.9-6.2, respectively). Limitations of the study were its retrospective design and possible incomplete correction for severity of disease. Conclusions: Mean overall glucose during ICU admission is related to mortality by a U-shaped curve in medical and surgical patients. In this cohort of patients a 'safe range' of mean glucose regulation might be defined approximately between 7.0 and 9.0 mmol/l.
- 24 November 2010
- Vol. 77 (2) , 212-9
Selective decontamination of the digestive tract as infection prevention in the critically ill. A level 1 evidence-based strategy.
Selective decontamination of the digestive tract (SDD) evolved into evidence-based medicine as a tool to prevent infections in critically ill patients. It significantly reduces mortality, pneumonia, bloodstream infections and the onset of resistance if the full four-component regimen is used. The use of only oral decontamination may reduce the incidence of pneumonia, but it has no significant impact on mortality. Moreover, the full SDD protocol significantly reduces the fecal carriage of multiresistant aerobic Gram-negative bacteria, whereas oral decontamination only is associated with increased carriage of multiresistant aerobic Gram-negative bacilli.
- 24 November 2010
- Vol. 77 (2) , 212-9
Selective decontamination of the digestive tract as infection prevention in the critically ill. A level 1 evidence-based strategy.
Selective decontamination of the digestive tract (SDD) evolved into evidence-based medicine as a tool to prevent infections in critically ill patients. It significantly reduces mortality, pneumonia, bloodstream infections and the onset of resistance if the full four-component regimen is used. The use of only oral decontamination may reduce the incidence of pneumonia, but it has no significant impact on mortality. Moreover, the full SDD protocol significantly reduces the fecal carriage of multiresistant aerobic Gram-negative bacteria, whereas oral decontamination only is associated with increased carriage of multiresistant aerobic Gram-negative bacilli.
- Open Access
- 1 January 2010
- Published by Springer Nature in Critical Care
- Vol. 14 (5) , 443
Withholding selective decontamination of the digestive tract from critically ill patients must now surely be ethically questionable given the vast evidence base
- 1 January 2010
- Published by Springer Nature in Critical Care
- Vol. 14 (5) , 443
Open AccessWithholding selective decontamination of the digestive tract from critically ill patients must now surely be ethically questionable given the vast evidence base
- 5 December 2006
- Published by Springer Nature in Intensive Care Medicine
- Vol. 33 (2) , 207-208
Chris Stoutenbeek and selective digestive decontamination
- 5 December 2006
- Published by Springer Nature in Intensive Care Medicine
- Vol. 33 (2) , 207-208
Chris Stoutenbeek and selective digestive decontamination
- 23 July 2004
- Published by Springer Nature in Intensive Care Medicine
- Vol. 30 (10) , 1984
Comment on “Surviving sepsis campaign guidelines for the management of severe sepsis and septic shock” by Dellinger et al.
- 23 July 2004
- Published by Springer Nature in Intensive Care Medicine
- Vol. 30 (10) , 1984
Comment on “Surviving sepsis campaign guidelines for the management of severe sepsis and septic shock” by Dellinger et al.
- 1 April 2001
- Vol. 67 (4) , 292-7
Selective decontamination of the digestive tract as infection prevention in the critically ill. Does it lead to resistance?
Several meta-analysis showed the efficacy of selective decontamination of the digestive tract (SDD) in the reduction of infections in critically ill patients, particularly for ventilator associated pneumonia and bloodstream infections, thereby reducing mortality and morbidity. The principle of SDD is that by means of application of non-absorbable antibiotics in the intestinal canal and oropharyngeal cavity, potentially pathogenic microorganisms are eliminated, thereby reducing the incidence of organ site infections. The endogenous anaerobic flora is preserved as a factor contributing to defence against colonization. The potential induction of antibiotic resistance (AR) due to SDD is a major concern in ICU. This review evaluates the onset of clinically relevant AR after SDD. The results of a recent meta-analysis and of several studies, which confirmed the virtual absence of any reported AR with SDD and that did not find AR after stopping SDD, are presented. The eradication of the reservoir of abnormal bacteria located in the gut by topical non-absorbable antibiotics appears to significantly reduce morbidity, mortality and resistance. Using only systemic antibiotics in ICU may contribute to maintain an abnormal population of bacteria among which AR is encouraged.
- 1 April 2001
- Vol. 67 (4) , 292-7
Selective decontamination of the digestive tract as infection prevention in the critically ill. Does it lead to resistance?
Several meta-analysis showed the efficacy of selective decontamination of the digestive tract (SDD) in the reduction of infections in critically ill patients, particularly for ventilator associated pneumonia and bloodstream infections, thereby reducing mortality and morbidity. The principle of SDD is that by means of application of non-absorbable antibiotics in the intestinal canal and oropharyngeal cavity, potentially pathogenic microorganisms are eliminated, thereby reducing the incidence of organ site infections. The endogenous anaerobic flora is preserved as a factor contributing to defence against colonization. The potential induction of antibiotic resistance (AR) due to SDD is a major concern in ICU. This review evaluates the onset of clinically relevant AR after SDD. The results of a recent meta-analysis and of several studies, which confirmed the virtual absence of any reported AR with SDD and that did not find AR after stopping SDD, are presented. The eradication of the reservoir of abnormal bacteria located in the gut by topical non-absorbable antibiotics appears to significantly reduce morbidity, mortality and resistance. Using only systemic antibiotics in ICU may contribute to maintain an abnormal population of bacteria among which AR is encouraged.
- 1 January 1988
- Published by Springer Nature in Drugs
- Vol. 35 (Supplement) , 29-34
Cefotaxime Combined with Selective Decontamination in Long Term Intensive Care Unit Patients
Emergence of bacterial resistance to antimicrobial agents was studied during a period of 30 months of continuous use of parenteral cefotaxime combined with oral non-absorbable polymyxin E and tobramycin (selective decontamination) in a surgical intensive care unit (ICU). No increase in drug-resistant micro-organisms was found. Colonisation of the oropharyngeal cavity or intestine or both by strains resistant to polymyxin E occurred in 8% of patients (invariably Proteus and Morganella species). Tobramycin-resistant strains (Escherichia coli, Acinetobacter and Pseudomonas species) were found in 4% of patients. Intestinal colonisation with cefotaxime-resistant bacilli (e.g. Enterobacter, Pseudomonas and Acinetobacter species) occurred in 10% of patients, but in most patients these strains were eliminated by therapy with the topical antibiotics within one week. The control of emergence of resistance has major implications for the antibiotic policy in the ICU: firstly, the number of different antimicrobials used is sharply reduced since the switching of antibiotics to treat suprainfections is seldom necessary; secondly, it is possible to use a third generation cephalosporin such as cefotaxime for systemic prophylaxis, without risk of induction of resistance.
- 1 January 1988
- Published by Springer Nature in Drugs
- Vol. 35 (Supplement) , 29-34
Cefotaxime Combined with Selective Decontamination in Long Term Intensive Care Unit Patients
Emergence of bacterial resistance to antimicrobial agents was studied during a period of 30 months of continuous use of parenteral cefotaxime combined with oral non-absorbable polymyxin E and tobramycin (selective decontamination) in a surgical intensive care unit (ICU). No increase in drug-resistant micro-organisms was found. Colonisation of the oropharyngeal cavity or intestine or both by strains resistant to polymyxin E occurred in 8% of patients (invariably Proteus and Morganella species). Tobramycin-resistant strains (Escherichia coli, Acinetobacter and Pseudomonas species) were found in 4% of patients. Intestinal colonisation with cefotaxime-resistant bacilli (e.g. Enterobacter, Pseudomonas and Acinetobacter species) occurred in 10% of patients, but in most patients these strains were eliminated by therapy with the topical antibiotics within one week. The control of emergence of resistance has major implications for the antibiotic policy in the ICU: firstly, the number of different antimicrobials used is sharply reduced since the switching of antibiotics to treat suprainfections is seldom necessary; secondly, it is possible to use a third generation cephalosporin such as cefotaxime for systemic prophylaxis, without risk of induction of resistance.